EUVIMEDEUVIMED entdecken
Open Access

Kidney-Protective Effects of SGLT2 Inhibitors

Biff F Palmer, Deborah J Clegg

Clinical Journal of the American Society of Nephrology · 2023-02 · 18 (2) · 279-289

DOI: 10.2215/cjn.09380822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 20.10.2022. Verfasst von Biff F Palmer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 118-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The sodium-glucose cotransporter 2 (SGLT2) inhibitors have become an integral part of clinical practice guidelines to slow the progression of CKD in patients with and without diabetes mellitus. Although initially developed as antihyperglycemic drugs, their effect on the kidney is multifactorial resulting from profuse glycosuria and natriuresis consequent to their primary site of action. Hemodynamic and metabolic changes ensue that mediate kidney-protective effects, including ( 1 ) decreased workload of proximal tubular cells and prevention of aberrant increases in glycolysis, contributing to a decreased risk of AKI; ( 2 ) lowering of intraglomerular pressure by activating tubular glomerular feedback and reductions in BP and tissue sodium content; ( 3 ) initiation of nutrient-sensing pathways reminiscent of starvation activating ketogenesis, increased autophagy, and restoration of carbon flow through the mitochondria without production of reactive oxygen species; ( 4 ) body weight loss without a reduction in basal metabolic rate due to increases in nonshivering thermogenesis; and ( 5 ) favorable changes in quantity and characteristics of perirenal fat leading to decreased release of adipokines, which adversely affect the glomerular capillary and signal increased sympathetic outflow. Additionally, these drugs stimulate phosphate and magnesium reabsorption and increase uric acid excretion. Familiarity with kidney-specific mechanisms of action, potential changes in kidney function, and/or alterations in electrolytes and volume status, which are induced by these widely prescribed drugs, will facilitate usage in the patients for whom they are indicated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2HumansKidneyHypoglycemic AgentsSodium

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsSodium

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Internal Medicine, Texas Tech Health Sciences Center, El Paso, Texas.

Zitieren

APA

Palmer, B. F., & Clegg, D. J. (2023). Kidney-Protective Effects of SGLT2 Inhibitors. Clinical Journal of the American Society of Nephrology, 18(2), 279-289. https://doi.org/10.2215/cjn.09380822

Vancouver

Palmer BF, Clegg DJ. Kidney-Protective Effects of SGLT2 Inhibitors. Clinical Journal of the American Society of Nephrology. 2023;18(2):279-289. doi:10.2215/cjn.09380822

BibTeX
@article{Palmer2023,
  author = {Palmer, Biff F and Clegg, Deborah J},
  title = {Kidney-Protective Effects of SGLT2 Inhibitors},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2023},
  volume = {18},
  number = {2},
  pages = {279--289},
  doi = {10.2215/cjn.09380822}
}
Kostenlos starten →